UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPROVAL					
OMB Number:	3235-0287				
Estimated average but	urden				
hours per response	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e Responses	,															
1. Name and Address of Reporting Person – GOLDBERG DAVID C				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O ENZO BIOCHEM, 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 05/26/2005							X_ Officer (give title below) Other (specify below) VP, Business Development						
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year) 05/31/2005							6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						dired, Disposed of, or Beneficially Owned							
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	Execu any			(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Owned Following Re Transaction(s)]	Ownership Form:	Beneficial	
				(Mon	th/Day/	(Year)	Code	V An	nount	(A) or (D)	Price	(Instr.	3 and 4)	or Indirect (D) or Indirect (I) (Instr. 4)		Ownership (Instr. 4)	
Common	Stock, Par	Value \$0.01	05/26/2005				M	7,0)35	A	\$ 6.84	35,65	8 (1)])	
Terrinider. I		•					ii	n this fo	rm are		quired	to res	spond ui		on contained orm display		1474 (9-02)
	toport on a s		class of securities b														
	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	ative Section of D	ecuritio	es Acquired rants, opti er 6. Date Expirat (Month	n this fo current I, Dispos	rm are ly vali ed of, o vertible	e not red id OMB or Benefi e securit	icially (ies) 7. Tit of Ur Secur	Owned and anderlying	Amount	8. Price of		s	11. Natur of Indirec Beneficia
1. Title of Derivative Security	Conversion or Exercise	Date	3A. Deemed Execution Date, if any	4. Transac Code	ative Secuts, cal	ecurition lls, was Numb	s Acquirectrants, opti er 6. Date Expirat (Month	this fo current , Dispose ons, conv Exercisation Date	rm are ly vali ed of, o vertible	e not red id OMB or Benefi e securit	icially (ies) 7. Tit of Ur Secur	Owned cle and anderlying rities	Amount	8. Price of Derivative Security	9. Number o Derivative Securities	f 10. Owners Form of Derivati Security Direct (or Indire	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ative Secuts, cal	ecurities. Number of Derivative curities acquired A) or hisposed f (D) (Instr. 3, and 5)	s Acquirectrants, optier 6. Date Expirat (Month 4,	n this fo current I, Dispose ons, conv Exercisa ion Date h/Day/Ye:	rm are dy vali	e not redid OMB or Benefice securit d	icially (ies) 7. Tit of Ur Secur	Owned cle and Anderlyin rities:	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Owners Form of Derivati Security Direct (or Indirect)	11. Natur of Indirec Beneficia Ownershi (Instr. 4)

Keporung Owners

D (O N /	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
GOLDBERG DAVID C C/O ENZO BIOCHEM 527 MADISON AVENUE NEW YORK, NY 10022			VP, Business Development		

Signatures

/s/ David C. Goldberg	06/01/2005
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- As of the date hereof, the Reporting Person directly beneficially owns 32,149 shares of Common Stock, 2,576 shares of Common Stock in Enzo Biochem's 401K plan, and has an indirect
- (1) beneficial interest in 933 shares as custodian for certain of his children.
- (2) The option vested in four equal annual installments, beginning on May 31, 1995.
- (3) As of the date hereof, the Reporting Person directly beneficially owns 77,373 options to purchase Common Stock, 44,663 of which are currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.